OptimizeRx (OPRX) Q3 2026 earnings review
OptimizeRx cuts its sales plan again, while cost cuts lift profit
OptimizeRx, which runs software for drugmakers to message doctors, earned higher profits even as customer spending fell again. Third-quarter revenue dropped 17% from a year ago to $21.6 million, while operating profit before one-offs rose 23% because the firm exited low-margin services and cut staff. However, chief executive Stephen Silvestro lowered the full-year sales plan for a third time, which by our math leaves fourth-quarter sales down 13% from a year ago.
| Revenue | $21.6M -17% from a year ago |
|---|---|
| Adjusted EBITDA | $6.3M +23% from a year ago |
| 12-month net revenue retention | 83% 90% last quarter and 121% a year ago |
| Full-year revenue outlook | Cut $7.5M new range: $87M to $93M (-18% at middle) |
⚖️ Verdict: 🔴 Bearish
The story got worse because the hoped-for year-end spending rebound failed to arrive, forcing another sales cut as existing clients spent 17% less over the past year than the year before. On the positive side, a major customer that spent nothing in the first half returned for the fourth quarter, and the company cut its debt in half since December while holding its full-year profit plan steady.
The question now is whether early contract signings for 2027 mark a real recovery in pharmaceutical marketing budgets or another false start like late 2025. Either the returning large client and new automated ad partnerships restore top-line growth next year, or ongoing drug-pricing pressure keeps shrinking average account spend. Fourth-quarter results and the initial 2027 revenue outlook will settle it.
🐂 Bull Case
Product Mix and Cost Cuts Lift Profit
OptimizeRx runs an electronic health record (EHR) network that lets drugmakers show messages to doctors during patient visits. Even as third-quarter revenue dropped 17.1% from a year ago, gross margin rose 8.0 percentage points to 75.2% because the company exited low-margin direct-to-consumer managed services last year. Chief executive Stephen Silvestro said the quarter showed the "benefits of our improved product mix and cost management initiatives".
- Cost of making its products (excluding depreciation): 24.8% of revenue, down from 32.8% a year ago
- Adjusted EBITDA (operating profit before depreciation, stock pay, and one-offs): $6.3 million, up 23.3%
- Adjusted EBITDA margin: 29.1% of revenue, up 9.5 percentage points from 19.6% a year ago
Lower delivery costs and earlier staff cuts allowed management to keep its full-year Adjusted EBITDA outlook of $21 million to $25 million despite cutting the sales target again. By our math, already-reported profit of $14.6 million for the first nine months leaves only $8.4 million needed in the fourth quarter to hit the middle of the range, down 29.5% from a year ago.
What to watch: fourth-quarter gross margin in the next earnings report. A reading above 74% would confirm that higher-margin software and partner sales can protect profits even while total sales shrink.
Debt Cut in Half and Dormant Client Returns
Strong cash collection allowed the healthcare technology group to repair its balance sheet over the first nine months of 2026. The firm generated $4.7 million of free cash flow in the third quarter by our math, and used its cash and a new bank loan to cut total debt in half from $25.7 million at year-end to $12.7 million. That reduced quarterly interest expense from $1.2 million a year ago to $0.2 million.
On the commercial side, a major customer that accounted for roughly a tenth of 2025 sales and spent nothing in the first half of 2026 is buying again. Silvestro pointed to "renewed spending in the fourth quarter from a previously significant customer" alongside early contract growth for the 2027 selling season. While that return did not prevent a 2026 sales cut, it removes the risk that the account was permanently lost.
What to watch: first-quarter 2027 revenue and contracted backlog updates on the fourth-quarter call. Those figures will show whether the returning client signed a full annual commitment or only placed a small year-end order.
🐻 Bear Case
Third Outlook Cut Confirms Weak In-Year Bookings
For two quarters, management kept its $95 million to $100 million full-year revenue target and argued that normal second-half pharmaceutical budget spending would make up for a slow start. This quarter disproved that view. Silvestro said "in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook" down to a new range of $87 million to $93 million.
- Initial 2026 revenue outlook (set November 2025): $118 million to $124 million
- March and May 2026 revisions: cut to $109–114 million, then $95–100 million
- Implied Q4 2026 revenue at the new $90 million middle of the range: $28.0 million, down 13.0% from a year ago by our math
Third-quarter sales of $21.6 million actually beat the roughly $20.6 million implied by the old plan's seasonal split by our math, which means the entire $7.5 million reduction falls on the fourth quarter. Silvestro added that the team is "encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season", where drugmakers request proposals for next year, but management offered the same assurance a year ago before cutting 2026 targets three times.
What to watch: whether management provides an exact dollar figure or percentage for 2027 contracted revenue on the next call. Without hard bookings numbers, claims of a 2027 rebound remain untested.
Existing Customers Keep Spending Less
Pharmaceutical clients have pulled back on marketing budgets amid drug-pricing policy uncertainty and shorter contract durations. OptimizeRx tracks this through net revenue retention (NRR), which measures how much money existing clients spent over the last 12 months compared to the prior 12 months. That figure dropped to 83% in the third quarter, down from 90% in the second quarter and 121% a year ago.
The contraction hit both large and smaller clients. Average 12-month revenue across the top 20 pharmaceutical manufacturers fell 18.9% from a year ago to $2.50 million, reducing their share of total sales from 56% to 53%. Because total 12-month revenue fell 14.0% to $94.2 million by our math, sales to smaller drugmakers and medical-device clients outside the top 20 also shrank by 8.1%, showing that smaller accounts are not growing fast enough to replace big-pharma cuts.
What to watch: 12-month net revenue retention in the fourth-quarter release. The metric must climb back toward 100% before the company can return to sustainable sales growth.
New Ad Partners Lack Disclosed Revenue Numbers
Management wants to grow by opening its doctor-messaging network to automated ad-buying platforms and selling subscriptions to its Dynamic Audience Activation Platform (DAAP), an artificial-intelligence tool that helps drugmakers target patients and doctors. This quarter Silvestro noted that "our partnerships with DeepIntent, The Trade Desk, and PulsePoint are broadening programmatic access to our proprietary network".
Adding two more ad-buying partners widens the company's reach, but the earnings release gave zero numbers on how much bidding volume or revenue these integrations generate. In addition, after reporting that DAAP sales grew 60% in the first quarter and over 30% in the second quarter, the release gave no growth rate for DAAP or subscription revenue in the third quarter.
What to watch: any disclosure of subscription revenue as a share of total sales in the fourth-quarter report, where management previously aimed to pass a 10% share exiting the year.
Risks this quarter didn't answer
Four standing governance, concentration, and capital questions received no update in the earnings release and await the quarterly filing or conference call.
- Internal control weakness: prior filings noted an identified material weakness in internal controls ahead of the January 2027 finance-chief transition; the release does not mention remediation.
- Top-five customer concentration: the top five clients produced roughly 47% of 2025 sales, and the quarterly concentration table appears only in the Form 10-Q filing.
- Partner minimum commitments: multi-year minimum payments owed to network partners ($27.4 million previously disclosed) are only updated in the filing footnotes.
- Share buybacks: treasury stock remained unchanged at 1.74 million shares, showing the $10 million repurchase plan authorized in March 2026 remains unused.
💲 Other KPIs
Uncollected customer bills fell 33.3% from $37.8 million at the end of 2025, sitting slightly above the $24.8 million recorded last quarter. Collecting those older winter bills brought in $12.5 million of operating cash over the first nine months, which funded the company's early debt repayments.
Sales generated per average full-time worker over the past 12 months dropped 13.9% from $820 thousand a year ago, continuing a slide from $801 thousand in the first quarter and $750 thousand in the second quarter. Revenue shrank faster than headcount despite this year's staff reductions.
The company recorded $697 thousand in staff severance and $80 thousand in marketing-chief search fees during the third quarter, down from $1.75 million combined in the second quarter. Across the first nine months, severance and search costs totaled $2.56 million, creating a wide gap between break-even GAAP net income and $8.8 million of profit excluding one-offs.
🔮 Guidance
Cut. Management lowered the middle of its full-year sales plan by $7.5 million, pointing to an 17.8% drop from 2025. By our math, that leaves $28.0 million of revenue for the fourth quarter, down 13.0% from last year's $32.2 million peak. It is the third cut since OptimizeRx first issued a $118 million to $124 million target in November 2025: -$9.5M, -$14.0M, held, then -$7.5M.
Unchanged. The profit target still calls for $23 million at the middle of the range, down 5.4% from $24.3 million in 2025. Because the business already earned $14.6 million across the first nine months, hitting the midpoint requires $8.4 million in the fourth quarter by our math, or a 30.1% margin on implied fourth-quarter sales versus 37.1% a year ago.
❓ Key Questions
How much 2027 revenue is already under signed contracts?
Silvestro highlighted growth in 2027 contracted revenue during the request-for-proposal season, but management made a similar claim in late 2025 before cutting 2026 sales targets by $31 million at the midpoint. Investors need the exact dollar or percentage coverage.
What are the dollar sales for DAAP and subscriptions?
Management previously aimed for subscription contracts to pass 10% of total revenue exiting 2026, and gave DAAP growth rates in the first two quarters. Neither figure appeared in the third-quarter release.
How much revenue are the new ad partners generating?
OptimizeRx added The Trade Desk and PulsePoint alongside DeepIntent to let automated ad buyers bid on its doctor network. Management has yet to share bid volume, revenue share, or gross margin for this channel.
Has the internal control weakness been fixed before the CFO change?
Recent quarterly filings flagged a material weakness in internal controls over financial reporting. With Chief Business Officer Andy D'Silva taking over as finance chief on January 1, 2027, investors need to know if remediation is complete.